Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
ascites
atezolizumab
bevacizumab
hepatocellular carcinoma
ramucirumab
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
20
10
2022
received:
20
08
2022
accepted:
22
10
2022
pubmed:
2
11
2022
medline:
2
11
2022
entrez:
1
11
2022
Statut:
ppublish
Résumé
Few studies have reported the efficacy and safety of ramucirumab (RAM) after atezolizumab plus bevacizumab (Atezo/Beva) treatment and the overall associated outcomes. Thus, we aimed to evaluate the therapeutic effects and safety of RAM post-treatment with Atezo/Beva. This retrospective study enrolled 46 patients with unresectable hepatocellular carcinoma who were treated with RAM. The patients were classified into the RAM administered following Atezo/Beva failure (n = 12) or RAM administered following other drug failure (n = 34) groups. Progression-free survival (PFS), overall survival (OS), and adverse event (AE) rates were assessed. There were significant differences in the objective response rates and disease control rates between the RAM administered following Atezo/Beva and RAM administered following others groups (objective response rate 33.3%. vs. 0.0%, p = 0.001; disease control rate 83.3% vs. 32.3, p = 0.001). Although there was no significant difference in the OS rates, the median PFS rates in the RAM administered following Atezo/Beva group was significantly higher than in the RAM administered following others group (PFS 3.9 months. vs. 1.9 months, p = 0.047). The AE rates were comparable between the two groups; ascites was the most common AE (45.6%). Using decision tree analysis, the presence of splenomegaly and body mass index (BMI) < 19.8 were the first and second splitting variables for RAM-related ascites, respectively. The therapeutic effect of RAM increased in patients with Atezo/Beva failure. Patients with splenomegaly and low BMI should be monitored for ascites during RAM treatment.
Types de publication
Journal Article
Langues
eng
Pagination
116-126Subventions
Organisme : None
Informations de copyright
© 2022 Japan Society of Hepatology.
Références
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450-62. https://doi.org/10.1056/nejmra1713263
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90. https://doi.org/10.1056/nejmoa0708857
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66. https://doi.org/10.1016/s0140-6736(16)32453-9
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-73. https://doi.org/10.1016/s0140-6736(18)30207-1
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282-96. https://doi.org/10.1016/s1470-2045(18)30937-9
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54-63. https://doi.org/10.1056/nejmoa1717002
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-905. https://doi.org/10.1056/nejmoa1915745
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859-70. https://doi.org/10.1016/s1470-2045(15)00050-9
Finn RS, Yau T, Chih-Hung H, Enrico N. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: final results from an expansion cohort of REACH-2. ASCO GI; 2022.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. https://doi.org/10.1016/j.ejca.2008.10.026
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(01):52-60. https://doi.org/10.1055/s-0030-1247132
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common Terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112(1):90-2. https://doi.org/10.1016/j.adengl.2019.05.021
Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31(5):1031-6. https://doi.org/10.1111/jgh.13250
Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M, Barbara M, et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology. 2015;62(3):784-91. https://doi.org/10.1002/hep.27729
Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, et al. Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. Mol Clin Oncol. 2021;14(4):79. https://doi.org/10.3892/mco.2021.2241
Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, et al. Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study. Cancers. 2020;12(7):12. https://doi.org/10.3390/cancers12071867
Hiraoka A, Kumada T, Tada T, Ogawa C, Tani J, Fukunishi S, et al. Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. Gastroenterol Rep. 2021;9(2):133-8. https://doi.org/10.1093/gastro/goaa042
Kuzuya T, Kawabe N, Hashimoto S, Funasaka K, Nagasaka M, Nakagawa Y, et al. Clinical outcomes of ramucirumab as post-treatment following atezolizumab/bevacizumab combination therapy in advanced hepatocellular carcinoma. Anticancer Res. 2022;42(4):1905-10. https://doi.org/10.21873/anticanres.15667
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight. 2018;3(19):3. https://doi.org/10.1172/jci.insight.59125
Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol. 2003;200(2):183-94. https://doi.org/10.1002/path.1339
Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J. Comparative evaluation of FGF-2-VEGF-A-and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res. 2004;94(5):664-70. https://doi.org/10.1161/01.res.0000118600.91698.bb
Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013;8(10):e77117. https://doi.org/10.1371/journal.pone.0077117
Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expet Opin Biol Ther. 2013;13(8):1187-96. https://doi.org/10.1517/14712598.2013.810717
Spratlin J. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep. 2011;13(2):97-102. https://doi.org/10.1007/s11912-010-0149-5
Chen CT, Feng YH, Yen CJ, Chen SC, Lin YT, Lu LC, et al. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatol Int. 2022;16(5):1199-207. https://doi.org/10.1007/s12072-022-10392-x
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Kajiwara M, Itano S, et al. Association between adverse events and prognosis in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Cancers. 2022;14(17):4284. https://doi.org/10.3390/cancers14174284
Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study. Liver Cancer. 2021;10(2):107-14. https://doi.org/10.1159/000512781
Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, et al. Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatol Res. 2021;51:880-9.
Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, et al. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep. 2021;11(1):14474. https://doi.org/10.1038/s41598-021-93794-5
Yasui Y, Kurosaki M, Tsuchiya K, Hayakawa Y, Hasebe C, Abe M, et al. Real-world data on ramucirumab therapy including patients who experienced two or more systemic treatments: a multicenter study. Cancers. 2022;14(12):2975. https://doi.org/10.3390/cancers14122975
Kudo M, Ikeda M, Galle PR, Yamashita T, Finn RS, Liang K, et al. Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: outcomes by treatment-emergent ascites. Hepatol Res. 2021;51(6):715-21. https://doi.org/10.1111/hepr.13638
Cikrikcioglu MA, Hursitoglu M, Erkal H, Inan B, Ozturk T, Cakirca M, et al. Splenomegaly in primary antiphospholipid syndrome without accompanying portal hypertension or comorbidity. Pathophysiol Haemost Thromb. 2010;37(2-4):104-9. https://doi.org/10.1159/000327506
Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005;43(1):98-103. https://doi.org/10.1016/j.jhep.2005.02.022
Ng WL, Collins PF, Hickling DF, Bell JJ. Evaluating the concurrent validity of body mass index (BMI) in the identification of malnutrition in older hospital inpatients. Clin Nutr. 2019;38(5):2417-22. https://doi.org/10.1016/j.clnu.2018.10.025